Capital Com MENA Securities Trading LLC is regulated by the Capital Market Authority.
Open platformOpen platform

Genfit plans Phase 2 trial of nangibotide in acute-on-chronic liver failure

By Public Technologies
  • Genfit will present clinical data supporting nangibotide’s advancement into Phase 2 for acute-on-chronic liver failure on November 8, 2026.
  • Previous studies in other indications provided safety data and promising efficacy signals across multiple organ systems.
  • November 6 presentations will show additional evidence of nitazoxanide’s anti-inflammatory activity from clinical blood samples, supporting development for acute-on-chronic liver failure.
  • A separate November 6 panel will discuss NIS non-invasive diagnostics for identifying at-risk MASH patients and monitoring treatment response.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genfit SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611020130PRIMZONEFULLFEED1001280946) on November 02, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.